Table 1.
Relative survival probability 3, 5 and 8 years after breast cancer diagnosis according to tumour characteristics
| Variable | Category | N (%) | 3-year | 5-year | 8-year |
|---|---|---|---|---|---|
| Survival (95% CI) | Survival (95% CI) | Survival (95% CI) | |||
| Histology | Ductal | 1276 (75.73) | 97 (95–98) | 93 (92–95) | 91 (88–93) |
| Lobular | 110 (6.53) | 95 (88–98) | 89 (80–94) | 87 (76–94) | |
| Other | 299 (17.74) | 100 (98–101) | 97 (94–99) | 97 (92–100) | |
| Tumour size | T1 | 876 (51.99) | 100 (99–101) | 98 (97–99) | 97 (95–99) |
| T2 | 424 (25.16) | 96 (93–98) | 91 (87–94) | 87 (81–91) | |
| T3 | 73 (4.33) | 88 (77–94) | 75 (63–85) | 71 (58–81) | |
| T4 | 39 (2.31) | 74 (56–86) | 59 (41–74) | 59 (40–75) | |
| Tis | 109 (6.47) | 101 (101–101) | 102 (102–102) | 100 (91–103) | |
| Missing | 141 (8.37) | 93 (86–97) | 87 (80–93) | 81 (69–90) | |
| Node infiltration | N0 | 877 (52.05) | 100 (99–100) | 97 (95–99) | 98 (96–100) |
| N1 | 441 (26.17) | 97 (95–99) | 94 (91–96) | 90 (85–94) | |
| N2 | 142 (8.43) | 93 (86–97) | 85 (77–91) | 78 (68–86) | |
| N3 | 49 (2.91) | 81 (67–91) | 77 (61–87) | 61 (40–78) | |
| Missing | 176 (10.45) | 92 (86–96) | 88 (81–93) | 79 (69–87) | |
| Tumour stage | 0 | 112 (6.65) | 100 (95–101) | 101 (96–102) | 98 (89–102) |
| I | 594 (35.25) | 101 (99–101) | 99 (97–101) | 100 (97–102) | |
| II | 498 (29.55) | 98 (96–100) | 95 (92–97) | 93 (88–96) | |
| III | 187 (11.10) | 94 (89–97) | 88 (82–93) | 81 (72–88) | |
| IV | 42 (2.49) | 63 (46–77) | 40 (24–55) | 24 (11–40) | |
| Oestrogen receptor | Positive | 1398 (82.97) | 99 (98–100) | 96 (94–97) | 93 (91–95) |
| Negative | 244 (14.48) | 86 (81–90) | 81 (75–86) | 80 (73–85) | |
| Progesterone receptor | Positive | 1237 (73.41) | 100 (98–100) | 97 (95–98) | 95 (92–97) |
| Negative | 401 (23.80) | 90 (86–93) | 85 (80–88) | 81 (76–85) | |
| Her2 | Negative | 1250 (74.18) | 97 (96–98) | 93 (92–95) | 91 (88–93) |
| Positive | 294 (17.45) | 97 (94–99) | 93 (89–96) | 89 (84–93) | |
| Intrinsic subtype | Luminal A | 997 (59.17) | 100 (98–100) | 96 (94–98) | 94 (92–97) |
| Luminal B | 331 (19.64) | 97 (95–99) | 94 (90–97) | 88 (83–93) | |
| Her2 | 81 (4.81) | 94 (86–99) | 87 (76–93) | 82 (70–91) | |
| Basal-like | 130 (7.72) | 78 (70–85) | 74 (65–81) | 74 (64–82) | |
| Luminal ONI | 91 (5.40) | 100 (94–101) | 101 (95–102) | 101 (92–104) | |
| Grade | I: Well differentiated | 329 (19.53) | 100 (98–101) | 99 (96–101) | 99 (95–102) |
| II: Moderately differentiated | 520 (30.86) | 100 (98–101) | 95 (92–97) | 93 (89–96) | |
| III: Poorly differentiated | 355 (21.07) | 93 (89–95) | 90 (86–94) | 88 (83–92) | |
| Missing | 481 (28.55) | 96 (93–98) | 91 (88–94) | 88 (83–91) |
ONI Otherwise non-identified, Luminal ONI hormonal receptors positive, Her2 missing, Non-luminal ONI hormonal receptors negative, Her2 missing